Report
FLASH - Pherecydes Pharma - Strong Buy - TP: €5.55
Pherecydes puts an end to its financing difficulties by joining forces with the French biotech Erytech Pharma, whose solid cash position will enable it to create a major player in phagotherapy in Europe. Thus, the company is able to perpetuate all its clinical programmes and will even proceed with an extension of PhagoDAIR.
Underlying
Pherecydes Pharma
Provider
Portzamparc Sponsored
Portzamparc is a subsidary of BNP Paribas which adapted the mission to contribute to responsible and sustainable growth of private clients, management companies and SMEs . They offer personalized support adapted to the objectives in particular for Small and Medium-Sized Enterprises.
Mohamed Kaabouni
Other Reports on these Companies
Other Reports from Portzamparc Sponsored
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.